Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

29
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
29
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

918
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
918
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

36
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
36
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232
Hepatitis01:25

Hepatitis

99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.

Kidney360·2023
Same author

Reduced metabolic flexibility is a predictor of weight gain among liver transplant recipients.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2023
Same author

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.

Gastroenterology·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Noninvasive Assessment of Liver Fibrosis in NAFLD.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023

Related Experiment Video

Updated: May 7, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.1K

Drug-induced steatohepatitis.

Vaishali Patel1, Arun J Sanyal

  • 1Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, Virginia Commonwealth University, MCV Box 980341, Richmond, VA 23298-0341, USA.

Clinics in Liver Disease
|October 9, 2013
PubMed
Summary

Nonalcoholic fatty liver disease (NAFLD) is a common liver condition linked to metabolic syndrome. This review examines drugs causing NAFLD and their mechanisms.

Keywords:
Drug-induced steatohepatitisMicrovesicular and macrovesicular steatosisNonalcoholic fatty liver diseaseNonalcoholic steatohepatitis

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Related Experiment Videos

Last Updated: May 7, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

13.1K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Area of Science:

  • Hepatology
  • Pharmacology
  • Internal Medicine

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the U.S.
  • NAFLD is associated with metabolic syndrome and chronic inflammation.
  • The understanding of NAFLD pathogenesis has evolved since its initial description in 1980.

Purpose of the Study:

  • To review current evidence on drugs inducing hepatic steatosis and steatohepatitis.
  • To explore the pathogenic mechanisms of drug-induced NAFLD.

Main Methods:

  • Literature review of studies on drug-induced liver injury.
  • Analysis of pathogenic pathways linking medications to NAFLD.

Main Results:

  • Certain medications are identified as causes of hepatic steatosis and steatohepatitis.
  • Specific mechanisms underlying drug-induced liver fat accumulation and inflammation are discussed.

Conclusions:

  • Drug-induced NAFLD is a significant clinical concern.
  • Understanding these drug effects is crucial for patient management and treatment strategies.